ERBB2 and breast carcinoma: A similar approach recently took place in breast cancer where the antibody-drug conjugate trastuzumab-DM1 (T-DM1) was designed to combine the biological activity of trastuzumab with the targeted delivery of a highly potent chemotherapeutic agent to HER2-overexpressing breast cancer cells.